.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Accenture
UBS
Covington
Fish and Richardson
Express Scripts
Cipla
Johnson and Johnson
US Army
Chinese Patent Office

Generated: July 23, 2017

DrugPatentWatch Database Preview

Suppliers and packages for generic ingredient: doripenem

« Back to Dashboard

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106NDAShionogi Inc.59630-309-1010 VIAL, SINGLE-USE in 1 CARTON (59630-309-10) > 10 mL in 1 VIAL, SINGLE-USE (59630-309-01)
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106NDAShionogi Inc.59630-320-1010 VIAL, SINGLE-USE in 1 CARTON (59630-320-10) > 10 mL in 1 VIAL, SINGLE-USE (59630-320-01)
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106NDAApotex Corp.60505-6160-410 VIAL, SINGLE-USE in 1 CARTON (60505-6160-4) > 10 mL in 1 VIAL, SINGLE-USE (60505-6160-0)
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106NDAApotex Corp.60505-6161-410 VIAL, SINGLE-USE in 1 CARTON (60505-6161-4) > 10 mL in 1 VIAL, SINGLE-USE (60505-6161-0)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
McKesson
Boehringer Ingelheim
Merck
Johnson and Johnson
AstraZeneca
Deloitte
Daiichi Sankyo
Covington
Queensland Health

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot